Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector newsTweets
Most relevant news about SANOFI
11/14 SANOFI : Principia agree to develop multiple sclerosis drug candidate
11/14 Lexicon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Prov..
11/14 IQVIA : Mylan Launches Generic Clolar for Injection
11/13 REGENERON PHARMACEUTICALS : and Sanofi to Present New Analyses from the Praluent..
11/12 Peugeot launches joint venture to build cars in Algeria
11/09DJSANOFI : Signs Agreement with Principia Biopharma for MS Drug Candidate
11/09 SANOFI : Principia agree to develop multiple sclerosis drug candidate
11/07 ALNYLAM PHARMACEUTICALS : and Sanofi Present Positive Complete Results from APOL..
11/06 REGENERON PHARMACEUTICALS : to Share Clinical Progress of REGN1979 and Cemiplima..
11/02 SANOFI : and Alnylam present positive complete results from APOLLO Phase 3 study..
11/02 SANOFI : - Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Impr..
11/02 SANOFI : Q3 2017 Business EPS up 1.1% at CER FY 2017 Guidance Confirmed
11/02 SANOFI : meets 3Q profit forecasts
11/02DJSANOFI : Diabetes Weighs on Sanofi's 3Q Profits
11/02DJSANOFI : 3Q Net Profit Down on Weakness of Diabetes Franchise
More most relevant news
All news about SANOFI
11/16 SANOFI : UGA, Sanofi Pasteur develop new broadly protective vaccines for H3N2 in..
11/16 SANOFI : brings innovative medication to Saudi Arabia
11/15 SANOFI : UGA Research Team Explores Impact of Age on Response to Influenza Vacci..
11/15 DR REDDY LABORATORIES : Launches clofarabine generic injection in us
11/14 SANOFI : Principia agree to develop multiple sclerosis drug candidate
11/14 Lexicon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Prov..
11/14 IQVIA : Mylan Launches Generic Clolar for Injection
11/14 SANOFI : Experts clarify myths around diabetes
11/13 SANOFI : Body’s inability to manage glucose cause of diabetes not sugar, f..
11/13 REGENERON PHARMACEUTICALS : and Sanofi to Present New Analyses from the Praluent..
More news
Sector news : Pharmaceuticals - NEC
12:17aDJADRs End Higher; JA Solar, NetEase Trade Actively
11/17 British stocks fall back as Carillion crashes, Sky soars
11/17DJROCHE : U.S. FDA Approves Roche's Gazyva for Untreated Follicular Lymphoma
11/17DJROCHE : to Acquire U.S. Software Company Viewics
11/16 Europe approves GlaxoSmithKline's new triple lung drug
11/16 Exclusive - Prescient messages about Indian companies circulate in WhatsApp g..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
11/16 YOUR DAILY PHARMA SCOOP : A Look At Sanofi, Ultragenyx Gets FDA Nod, Capricor Tu..
11/15 SANOFI Q3 2017 : Weak Signals
11/15 Tracking Warren Buffett's Berkshire Hathaway Portfolio - Q3 2017 Update
11/14 HEALTHCARE DOGFIGHT : GlaxoSmithKline Regains Top By Gains In November As O&M & ..
11/13 Sanofi Wants To Make A Major Footprint In The Multiple Sclerosis Space
11/12 REGENERON FALLS ON Q3 REPORT : Weighing The Pros And Cons
Financials (€)
Sales 2017 35 939 M
EBIT 2017 9 366 M
Net income 2017 7 904 M
Debt 2017 4 659 M
Yield 2017 4,02%
P/E ratio 2017 12,15
P/E ratio 2018 16,16
EV / Sales 2017 2,78x
EV / Sales 2018 2,72x
Capitalization 95 278 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 28
Average target price 85,3 €
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-1.91%112 309
JOHNSON & JOHNSON20.74%373 077
NOVARTIS10.73%218 225
PFIZER8.87%211 963
ROCHE HOLDING LTD.-2.06%200 423
MERCK AND COMPANY-6.91%150 468